AVI BioPharma to Present at UBS Global Life Sciences Conference
September 14 2010 - 10:00AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, announced today that the company is scheduled to
present at the UBS Global Life Sciences Conference, Monday,
September 20, 2010, at 10:30 a.m. Eastern Time in New York City. J.
David Boyle II, AVI's Interim President and Chief Executive
Officer, and Chief Financial Officer, will provide a company
overview.
The conference presentation will be webcast live under the
events section of AVI's website at www.avibio.com, and will be
archived there following the presentation. Please connect to AVI's
website several minutes prior to the start of the broadcast to
ensure adequate time for any software download that may be
necessary.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, we are able to target
a broad range of diseases and disorders through distinct RNA-based
mechanisms of action. Unlike other RNA-based approaches, our
technologies can be used to directly target both messenger RNA
(mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging our highly differentiated
RNA antisense-based technology platform, we have built a pipeline
of potentially transformative therapeutic agents, including a
clinical stage Duchenne muscular dystrophy candidate and
anti-infective candidates for influenza and hemorrhagic fever
viruses. For more information, visit www.avibio.com.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sarepta Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More AVI BioPharma, Inc. News Articles